Fig. 6

Synergistic effectiveness of RB-312 with anti-PD-L1 against FaDu xenograft. A Mice intratumorally dosed with RB‐312 or respective control groups were administrated with or without atezolizumab and average tumor growth was followed till day 29. B After day 29, mice in control groups began to die and average growth is not informative. Scatter plots were subsequently used as exemplified for day 29. C RB‐312 effect on survival of individual mice and D cumulative survival—survival analysis until day 77. E Quantification of IFN‐γ systemic levels (left) and quantification of IFN‐γ secretion (right) after HER2 beads stimulation of retention samples cRB-312 and RB-312. F Quantification of IL-12 systemic levels (left) and quantification of IL-12 secretion (right) after HER2 beads stimulation of retention samples cRB-312 and RB-312. G Intratumoral persistence of hCD45⁺ CAR‐T cells and H percentage of PD‐1 expressing hCD45⁺ CAR‐T cells at necropsy